Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone-refractory Prostate Cancer

Interventions

DRUG: VIR-5500
COMBINATION_PRODUCT: Enzalutamide
COMBINATION_PRODUCT: Darolutamide

Sponsor

Vir Biotechnology, Inc.